Inhibition of Carbonic Anhydrase, Acetylcholinesterase and Butyrylcholinesterase by BisPMB, A Synthetic Analogue of Ajoene

Abstract

BisPMB (1,8-(bis-p-methoxyphenyl)-2,3,7-trithiaocta-4-ene 7-oxide) is a synthetic analogue of the natural compound ajoene, which is a bioactive natural product obtained from rearrangement of the unstable and reactive organosulfur compound allicin produced when garlic is freshly crushed. BisPMB has been shown to have superior cancer-cell cytotoxicity compared with ajoene and a modest selectivity towards cancer cells over non-cancerous ones. In this study, the inhibition effects of E/Z-bisPMB and Z-bisPMB against human carbonic anhydrase isozymes I and II (hCA I and II), acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were investigated in which E/Z-bisPMB and Z-bisPMB showed similar inhibition profiles against the four enzymes tested, with the IC₅₀ values ranging from 10.9 to 439.7 nM and the K_i values ranging from 5.4 to 195.4 nM. Furthermore, bisPMB was more potent at inhibiting CA I, CA II and AChE compared with commercially available inhibitors.

Keywords

• Acetylcholinesterase
• Ajoene
• BisPMB
• Butyrylcholinesterase
• carbonic anhydrase

References

1. 1. Block E. The Chemistry of Garlic and Onions. Sci Am. 1985 Mar;252(3):114–21.
2. 2. Hassan HT. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk Res. 2004 Jul;28(7):667–71.
3. 3. Yoshida S, Kasuga S, Hayashi N, Ushiroguchi T, Matsuura H, Nakagawa S. Antifungal activity of ajoene derived from garlic. Appl Env Microbiol. 1987 Mar;53(3):615–7.
4. 4. Visbal G, San-Blas G, Murgich J, Franco H. Paracoccidioides brasiliensis, paracoccidioidomycosis, and antifungal antibiotics. Curr Drug Targets Infect Disord. 2005 Sep;5(3):211–26.
5. 5. Naganawa R, Iwata N, Ishikawa K, Fukuda H, Fujino T, Suzuki A. Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlic. Appl Environ Microbiol. 1996 Nov;62(11):4238–42.
6. 6. Yang J-Y, Della-Fera MA, Nelson-Dooley C, Baile CA. Molecular mechanisms of apoptosis induced by ajoene in 3T3-L1 adipocytes. Obes Silver Spring Md. 2006 Mar;14(3):388–97.
7. 7. Powolny AA, Singh SV. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett. 2008 Oct 8;269(2):305–14.
8. 8. Kumar S, Chatterjee S, Kumar S. Dual anti-cholinesterase activity of ajoene by In silico and In vitro studies. Pharmacogn Res. 2018 Apr;10(2):225-229.

9. 9. Kaschula CH, Hunter R, Stellenboom N, Caira MR, Winks S, Ogunleye T, Richards P, Cotton J, Zilbeyaz K, Wang Y, Siyo V, Ngarande E, Parker MI. Structure-activity studies on the anti-proliferation activity of ajoene analogues in WHCO1 oesophageal cancer cells. Eur J Med Chem. 2012 Apr;50:236–54.
10. 10. De Simone G, Di Fiore A, Capasso C, Supuran CT. The zinc coordination pattern in the η- carbonic anhydrase from Plasmodium falciparum is different from all other carbonic anhydrase genetic families. Bioorg Med Chem Lett. 2015 Apr;25(7):1385–9.
11. 11. Del Prete S, Vullo D, Fisher GM, Andrews KT, Poulsen S-A, Capasso C, Supuran CT. Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the η-carbonic anhydrases. Bioorg Med Chem Lett. 2014 Sep;24(18):4389–96.
12. 12. Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. J Enzyme Inhib Med Chem. 2016 Oct;31(5):689–94.
13. 13. Supuran CT, Capasso C. Carbonic Anhydrase from Porphyromonas Gingivalis as a Drug Target. Pathog Basel Switz. 2017 Jul;6(3):30-43.
14. 14. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev. 2003 Mar;23(2):146–89.
15. 15. Scozzafava A, Mastrolorenzo A, Supuran CT. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin Ther Pat. 2004 May;14(5):667–702.
16. 16. Supuran CT. Therapeutic applications of the carbonic anhydrase inhibitors. Therapy. 2007 May;4(3):355–78.
17. 17. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008 Feb;7(2):168–81.
18. 18. Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016 Nov;31(3):345–60.
19. 19. Supuran CT. Carbonic anhydrase activators. Future Med Chem. 2018 Mar;10(5):561–73.
20. 20. García-Ayllón M-S, Small DH, Avila J, Sáez-Valero J. Revisiting the Role of Acetylcholinesterase in Alzheimer’s Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci. 2011 Sept;4:22.
21. 21. Bayram E, Senturk M, Kufrevioglu OI, Supuran CT. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct;16(20):9101–5.
22. 22. Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. J Biol Chem. 1967 Sep;242(18):4221–9.
23. 23. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec;22(23):3099–108.
24. 24. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88–95.
25. 25. Hunter R, Kaschula CH, Parker IM, Caira MR, Richards P, Travis S, Taute F, Qwebani T. Substituted ajoenes as novel anti-cancer agents. Bioorg Med Chem Lett. 2008 Oct;18(19):5277–9.
26. 26. Mboge MY, Mahon BP, McKenna R, Frost SC. Carbonic Anhydrases: Role in pH Control and Cancer. Metabolites. 2018 Feb;8(1):19.
27. 27. Prince MJ. World Alzheimer Report 2015: The Global Impact of Dementia [Internet]. 2015 [cited 2018 Nov 18]. Available from: https://www.alz.co.uk/research/world-report-2015